Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers


  Free Subscription


1 Acta Neurol Scand
1 BMC Neurol
2 Headache
2 Nat Rev Neurol
1 Rev Neurol

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Acta Neurol Scand

  1. D'AMICO D, Grazzi L, Guastafierro E, Sansone E, et al
    Withdrawal failure in patients with chronic migraine and medication overuse headache.
    Acta Neurol Scand. 2021 May 25. doi: 10.1111/ane.13475.
    PubMed         Abstract available

    BMC Neurol

  2. ALI EN, Carle CF, Lueck CJ, Kolic M, et al
    Assessing migraine patients with multifocal pupillographic objective perimetry.
    BMC Neurol. 2021;21:211.
    PubMed         Abstract available


  3. CHIANG CC, Halker Singh R, Lalvani N, Shubin Stein K, et al
    Patient experience of telemedicine for headache care during the COVID-19 pandemic: An American Migraine Foundation survey study.
    Headache. 2021 May 21. doi: 10.1111/head.14110.
    PubMed         Abstract available

  4. POPOFF E, Johnston K, Croop R, Thiry A, et al
    Matching-adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health-related quality of life in the treatment of migraine.
    Headache. 2021 May 22. doi: 10.1111/head.14128.
    PubMed         Abstract available

    Nat Rev Neurol

  5. RAPOPORT AM, Lipton RB
    Potassium channel openers - novel triggers of aura and migraine.
    Nat Rev Neurol. 2021 May 26. pii: 10.1038/s41582-021-00517.

  6. ABU-ARAFEH I, Gelfand AA
    The childhood migraine syndrome.
    Nat Rev Neurol. 2021 May 26. pii: 10.1038/s41582-021-00497.
    PubMed         Abstract available

    Rev Neurol

  7. MARIN-GRACIA M, Hernando-Quintana N, Lopez-Bravo A, Garcia-Arguedas C, et al
    [Degree of compliance with treatment at three months in migraine patients].
    Rev Neurol. 2021;72:377-383.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Migraine is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.